Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.64% | 45.96% | 35.65% | 60.20% | 79.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.52% | -3.03% | 37.41% | 59.14% | 62.19% |
| Operating Income | 11.52% | 3.03% | -37.41% | -59.14% | -62.19% |
| Income Before Tax | 15.33% | 11.02% | -7.85% | -6.81% | -45.88% |
| Income Tax Expenses | -100.97% | -95.05% | -- | -- | -- |
| Earnings from Continuing Operations | 15.44% | 11.12% | -7.98% | -6.95% | -46.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -83.37% | -67.53% | 4.70% | 43.96% | 52.57% |
| Net Income | 13.65% | 9.63% | -8.05% | -6.21% | -45.91% |
| EBIT | 11.52% | 3.03% | -37.41% | -59.14% | -62.19% |
| EBITDA | -12.32% | -23.58% | -37.50% | -59.83% | -62.63% |
| EPS Basic | 18.38% | 16.02% | 21.26% | 19.91% | -21.40% |
| Normalized Basic EPS | 37.55% | 34.38% | 21.37% | 20.39% | -21.24% |
| EPS Diluted | 17.71% | 15.34% | 21.26% | 19.91% | -21.40% |
| Normalized Diluted EPS | 37.55% | 34.38% | 21.37% | 20.39% | -21.24% |
| Average Basic Shares Outstanding | 37.55% | 40.55% | 40.32% | 35.36% | 22.63% |
| Average Diluted Shares Outstanding | 37.55% | 40.55% | 40.32% | 35.36% | 22.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |